Citius Oncology Inc (NASDAQ: CTOR)’s stock price has dropped by -7.60 in relation to previous closing price of 0.68. Nevertheless, the company has seen a loss of -21.00% in its stock price over the last five trading days. prnewswire.com reported 2025-02-14 that CRANFORD, N.J., Feb. 14, 2025 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2024.
Is It Worth Investing in Citius Oncology Inc (NASDAQ: CTOR) Right Now?
The 36-month beta value for CTOR is also noteworthy at 0.38. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CTOR is 3.52M, and at present, short sellers hold a 0.79% of that float. The average trading volume of CTOR on April 10, 2025 was 1.32M shares.
CTOR’s Market Performance
The stock of Citius Oncology Inc (CTOR) has seen a -21.00% decrease in the past week, with a -15.73% drop in the past month, and a -53.53% fall in the past quarter. The volatility ratio for the week is 13.68%, and the volatility levels for the past 30 days are at 19.61% for CTOR. The simple moving average for the past 20 days is -9.52% for CTOR’s stock, with a -81.46% simple moving average for the past 200 days.
Analysts’ Opinion of CTOR
Many brokerage firms have already submitted their reports for CTOR stocks, with Maxim Group repeating the rating for CTOR by listing it as a “Buy.” The predicted price for CTOR in the upcoming period, according to Maxim Group is $3 based on the research report published on November 27, 2024 of the previous year 2024.
CTOR Trading at -34.43% from the 50-Day Moving Average
After a stumble in the market that brought CTOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.71% of loss for the given period.
Volatility was left at 19.61%, however, over the last 30 days, the volatility rate increased by 13.68%, as shares sank -20.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.57% lower at present.
During the last 5 trading sessions, CTOR fell by -21.25%, which changed the moving average for the period of 200-days by -94.41% in comparison to the 20-day moving average, which settled at $0.6984. In addition, Citius Oncology Inc saw -45.04% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CTOR
Based on Citius Oncology Inc (CTOR), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -0.1.
Currently, EBITDA for the company is -20.57 million with net debt to EBITDA at -0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.39.
Conclusion
In summary, Citius Oncology Inc (CTOR) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
